Collegium Pharma (COLL) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Collegium Pharma (COLL) Misses Q2 EPS by 16c
August 12, 2015 5:00 PM EDT
CANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update.
Michael Heffernan, Collegium's Chairman and CEO, stated, "During the second quarter, Collegium achieved a number of important milestones. The successful completion of our IPO in May 2015 provides us with substantial additional resources to launch Xtampza ER pending final approval by the FDA and to move another product candidate into the clinic. Additionally, the commercial team has made significant progress in preparing for a potential 2016 launch of... More
August 12, 2015 5:00 PM EDT
CANTON, Mass., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the second quarter of 2015 and provided a corporate update.
Michael Heffernan, Collegium's Chairman and CEO, stated, "During the second quarter, Collegium achieved a number of important milestones. The successful completion of our IPO in May 2015 provides us with substantial additional resources to launch Xtampza ER pending final approval by the FDA and to move another product candidate into the clinic. Additionally, the commercial team has made significant progress in preparing for a potential 2016 launch of... More
